• Canada Nickel in December 2022 announced positive drilling results from exploration at its Reid and Sothman properties
• The company in November 2022 announced recovery of valuable by-products from a processing pilot test, including cobalt, palladium, platinum and chromium
• Canada Nickel announced in November 2022 improvements to its accelerated CO2 capture process
• Canada Nickel announced in October 2022 it closed a secured loan with Auramet International of $10 million
• Canada Nickel has engaged Deutsche Bank and Scotiabank as financial advisors for the Crawford Nickel Sulphide Project
• Projections indicate that, by 2035, world demand for nickel will double from current levels to 6 million tons annually

Canada Nickel Company (TSX.V: CNC) (OTCQX: CNIKF) is advancing the next generation of nickel-cobalt sulfide projects to deliver the metals needed to power the electric vehicle (“EV”) revolution and feed the high growth stainless steel market. The company is one of only a few new sources of potential supply outside Indonesia and China. Canada Nickel possesses industry leading nickel expertise and is focused on low risk, well established mining jurisdictions. The company has launched wholly owned subsidiary NetZero Metals Inc. to develop zero-carbon production of nickel, cobalt and iron and has applied in multiple jurisdictions to trademark the terms NetZero Nickel, NetZero Cobalt and NetZero Iron. Canada Nickel is also pursuing development of processes to allow net zero carbon production of these elements. Canada Nickel is currently anchored by its 100% owned flagship Crawford Nickel-Cobalt Sulfide Project with large-scale potential located in the heart of Ontario’s prolific Timmins-Cochrane mining camp, adjacent to major infrastructure. The company believes the EV industry and many other consumer sectors have an urgent need for zero-carbon metal this decade, not in 20-25 years as contemplated by some resource companies. Canada Nickel also believes that nickel supplies from Indonesia and other Pacific island nations, typically controlled by Chinese-owned companies, are not the answer for batteries needed by GM, Ford and the European automakers working to develop and manufacture EV models. The company is headquartered in Toronto. Crawford Nickel-Cobalt Sulfide Project The Crawford Nickel-Cobalt Sulfide Project is the largest sulfide discovery since the early 1970s and contains the fifth-largest nickel sulfide resource in the world, based on Measured & Indicated resources, according to the latest update. The Crawford project is expected to be one of the largest base metal mines in Canada based on results of a Preliminary Economic Assessment. Early projections by Canada Nickel estimate that the project has the potential to produce 50,000 tons of nickel per year. The company is now in the final stages of completing the project’s feasibility study. The project is projected to produce 2.8 tons of CO2 per ton of nickel equivalent production, which is 89% lower than the industry average of 34 tons of CO2 per ton of nickel equivalent production. The company is taking significant steps toward developing the Crawford project as a net zero carbon producer. In addition to harnessing the natural ability of the project’s geology to act as a carbon sink through spontaneous reaction of the host rock once exposed to atmospheric conditions called mineral carbonation, Canada Nickel has discovered a new way to enhance carbon capture, termed In Process Tailings (“IPT”) Carbonation. This act of conditioning the tailings with a concentrated stream of carbon dioxide before deposition has been demonstrated at lab scale to achieve carbon capture at a rate 8-12 times faster than naturally occurring sequestration, achieving more than 60% of the capture that had previously taken six days. These latest results move the company further toward production of Net Zero Nickel(TM) and generation of 21 tonnes of CO2 credits per tonne of nickel, which would produce an estimated average of 710,000 tonnes of CO2 credits annually and 18 million total tonnes of CO2 credits over the expected life of mine. IPT Carbonation does not require complex new technologies and major process modifications and could encourage the development of a net zero carbon industrial cluster centered around the Crawford project. Canada Nickel in January 2023 announced that its latest test work results support the incorporation of carbon capture and storage into the Crawford project. The company believes that utilization of existing process streams should allow IPT to be efficiently engineered and incorporated into the project’s flowsheet, with an integrated feasibility study for the project expected in the second quarter of 2023. In December 2022, Canada Nickel announced its engagement on Deutsche Bank Securities Inc. (“Deutsche Bank”) and Scotiabank – two of the world’s leading investment banks with a broad base of mining and industrial expertise – as financial advisors for the equity component of the project financing for the Crawford project. In the same release, the company announced the completion of another significant permitting milestone by filing the detailed project description with the Impact Assessment Agency of Canada. Canada Nickel targets receipt of permits by mid-2025, with construction to immediately follow. Additional Projects The Reid Nickel Property is located just 16 kilometers southwest of Crawford, or 37 kilometers northwest of Timmins, and contains an ultramafic body with a target geophysical footprint of 3.9 square kilometers. Preliminary assay results from Canada Nickel’s summer/fall drilling program confirm the presence of mineralized dunite, as well as currently undefined higher-grade sections. Partial assay results confirm expected nickel grades. Nickel mineralization in serpentinized dunite was found in all 16 holes drilled to date. The Sothman Nickel Property is located 70 kilometers south of Timmins. Five drill holes on the eastern half of the target anomaly confirmed the continuation of ultramafic lithologies, primarily peridotite, with moderate to strong serpentinization and variable amounts of mineralization throughout. The company in December 2022 announced positive drilling results from its ongoing regional exploration campaign at its Reid and Sothman properties. These latest results continue to reinforce the success of Canada Nickel’s geophysical targeting approach and increase the probability of success at the company’s other 20-plus properties within its 42 square kilometers of geophysical targets. Building on this momentum, Canada Nickel in December 2022 announced its entry into a deal to acquire a 100% interest in the past producing Texmont property situated between the company’s properties south of Timmins. As noted in the news release, the acquisition of the Texmont property provides near-term smaller scale production potential and is highly complementary to the company’s large-scale Crawford and regional nickel sulphide projects. Market Opportunity Global demand leaves the market fundamentally short of nickel in the medium- and long-term. Global primary nickel demand will likely reach 3 million tons in 2022, up from 2.4 million tons in 2020, according to the International Nickel Study Group (“INSG”). The INSG says primary nickel production is forecast to hit 3.1 million tons in 2022. Indonesia, the world’s largest nickel miner, halted exports of unprocessed nickel ore in January 2020, due to a government-imposed ban. Indonesia has floated the concept of a nickel cartel whose member nations would exert influence over world nickel supply and prices, similar to OPEC’s pricing power over oil. Benchmark Minerals, a leading EV supply chain research firm, projects that, by 2035, world demand for nickel will double from current levels to 6 million tons annually. That growing demand represents a need for new nickel production equivalent to 70 mines the size of Canada Nickel’s Crawford Project. Management Team Mark Selby is Chairman, CEO and Director of Canada Nickel. He was formerly President and CEO of RNC Minerals, where he led a team that successfully raised over $100 million and advanced the Dumont nickel-cobalt project from initial resource to a fully permitted, construction-ready project. He has held senior management roles with Quadra Mining, Inco and Purolator Courier, and was a partner at Mercer Management Consulting. Since 2001, he has been recognized as one of the leading authorities on the nickel market. He graduated from Queen’s University with a Bachelor of Commerce. Wendy Kaufman is CFO of Canada Nickel. She has 25 years of experience leading publicly listed mining companies in project financing, capital structuring, capital markets, accounting and internal controls, tax, and financial reporting and public disclosure. She was also previously CFO at Khiron Life Sciences Corp. and held CFO and senior finance positions at Pasinex Resources Limited, Primero Mining Corporation and Inmet Mining Corporation. She holds a Bachelor of Business Administration from Wilfrid Laurier University and is a Chartered Professional Accountant. Steve Balch is VP Exploration at Canada Nickel. He is an Ontario registered geoscientist with 32 years of experience in geophysics, specializing in magnetic and electromagnetic methods. He founded Triumph Instruments and developed the AirTEM system, a multi-coil helicopter-borne EM system that is in use worldwide. He has also been active in borehole geophysics and helped develop new technologies including north-seeking gyros, temperature compensated induction conductivity probes, UAV-based magnetometers and high sensitivity magnetic gradiometers. Christian Brousseau is VP Capital Projects at Canada Nickel. He is a professional engineer (P.Eng) with over 30 years of experience in engineering, design and construction in the Canadian mining industry, including six years as Project Director for the Dumont Project and three years as the Engineering and Construction Manager for Detour Gold. Prior to Detour, he held various construction management positions at Osisko’s Malartic Project and at Goldcorp’s Éléonore Project. He also spent eight years at Falconbridge supervising and managing various capital projects. For more information, visit the company’s website at www.CanadaNickel.com. NOTE TO INVESTORS: The latest news and updates relating to CNIKF are available in the company’s newsroom at https://ibn.fm/CNIKF

• MetAlert is a pioneer in location-sensitive health monitoring devices and wearable technology products targeting the Alzheimer’s, Dementia, and Autism (“ADA”) market
• The company is looking to provide cutting-edge telehealth technologies and is continuously working to roll out improved and more innovative products for its users
• Its SmartSole(R) product facilitates discreet tracking and remote monitoring of ADA patients
• The company has also launched SmartSole plus(R), which adds Bluetooth and Wi-Fi capabilities for better tracking
• MetAlert also distributes RoomMate, a wall-mounted 3D infrared supervision product that enables caregivers to look after patients without intruding on their personal space

The policy changes spearheaded by the US government at the height of the COVID-19 pandemic boosted telehealth, including telemedicine. As a result, by April 2020, telehealth services constituted 32% of Medicare claims, up from less than 1% before the pandemic, and by July 2021, the figure had plateaued to between 13% and 17% (https://ibn.fm/QtTZL). Against this backdrop, a recent article (https://ibn.fm/9deW5) in Equities asks: “But will its momentum continue now that the pandemic has lost its urgency?” While industry forecasts project that the telehealth space will expand at CAGRs ranging from 19% and 24% to as high as 32%, the author of the article is quick to point out that the adoption of new technologies in the health sector still faces myriad challenges. From the fact that the sector is slow to adopt changes and patients change their attitudes rather slowly to the sheer cost and disruption associated with health and medical practice technologies. However, the author notes that just as the smartphone space needed a jolt from tech juggernauts Google LLC, a subsidiary of Alphabet Inc. (NASDAQ: GOOGL), and Apple (NASDAQ: AAPL) to push adoption and innovation, so too does the telehealth space. While advanced, the existing telehealth technologies pale in comparison to what the next level of innovation and solutions is likely to be. “What everyone wants to know, of course, is what will happen next – and even more than that – when the next thing happens, who will the industry leaders be?” the Equities article asks. Los Angeles, California-headquartered MetAlert (OTC: MLRT) is working to be one of the industry leaders, leveraging existing and emerging technologies, such as GPS, Bluetooth, Wi-Fi, the ability of wireless networks to transmit large amounts of data in nanoseconds, and more, to provide innovative solutions to scores of patients. A pioneer in location-sensitive health monitoring devices and wearable technology products, MetAlert primarily targets people around the world living with Alzheimer’s, Dementia, or Autism (“ADA”) – over 34 million people, according to the company. It is well documented that ADA patients have a tendency to wander and become lost (https://ibn.fm/WcDC6) putting tremendous stress on families (https://ibn.fm/yf1Bz). To ameliorate the strain and stress and perhaps eliminate them altogether, MetAlert developed GPS SmartSole(R), a wearable medical monitoring device integrated into an orthotic insole, facilitating discreet tracking and remote monitoring of ADA patients. The SmartSole enables tracking by utilizing a 4G cellular network and is powered by a Lithium-ion battery that lasts between 2-4 days on a single charge, according to the company. In addition, this product can be configured to send alerts via email or text whenever someone enters or exits specific areas, giving caregivers the utmost peace of mind (https://ibn.fm/cQDdk). MetAlert has further enhanced the capabilities of SmartSole by adding Wi-Fi and Bluetooth capabilities, creating what it has named SmartSole plus(R). The revamped product’s use of Wi-Fi enables indoor tracking within large concrete structures, while Bluetooth facilitates connection to other wearable medical devices. Still, the company is pushing the boundaries of innovation, and is currently developing the next generation of its insole product named BioStride. According to MetAlert, BioStride will be designed to continuously collect health data that may help identify patterns before and during episodes and, utilizing an artificial intelligence-powered backend, analyze trends and send alerts in the event of a crisis. This way, MetAlert plans to expand its tracking and monitoring platform (https://ibn.fm/vvOre). MetAlert also distributes RoomMate(R), a wall-mounted 3D infrared supervision product that enables caregivers to look after patients without intruding on their personal space. It sends alerts about motley behaviors that may lead to falls or injuries, reducing staffing requirements and improving security, sleep, and quality of life. Most importantly, the RoomMate product functions effectively even among patients who have not worn wearables. For more information, visit the company’s website at www.MetAlert.com. NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

• Cannabis companies are regarded as being particularly vulnerable to cyberattacks, including potential ransomware incidents, because of their high cash-flow operations and their small business status, heightened by remote work due to Covid
• Cybersecurity services and technology provider SideChannel serves the needs of emerging businesses that may be hard-pressed to hire a full-time cybersecurity expert and need an affordable alternative
• SideChannel provides virtual chief information security officer (“vCISO”) services on a contract basis, drawing on a collective 450 years of experience

When the COVID-19 pandemic caused a wide array of industries to shut down their operations and then reopen with heightened emphasis on remote work, it created a generous opportunity for cyber criminals to exploit the increased business dependence on the Internet for core functions. Chainalysis, a company that tracks digital transactions on the blockchain, reported ransomware payments from victims surged by 311 percent between 2019 and 2020 to reach nearly $350 million, for example. Ransomware is a cyberattack in which a target’s computer files are accessed and then locked up, preventing the victim from using their own data files unless a ransom is paid to obtain a password key that will unlock them (https://ibn.fm/QORIv). Recent ransomware attack targets have ranged from a small school district in Massachussetts (https://ibn.fm/2CMlA) to multinational news media corporation The Guardian (https://ibn.fm/0dKFh). Cannabis companies are considered by many to comprise a particularly vulnerable target because of their small operations and high cash flows, as well as their challenges in obtaining standard business services because of the transitional legal outlook regarding their product (https://ibn.fm/3aKbD). Cybersecurity services and technology provider SideChannel (OTCQB: SDCH) is helping to make high quality protection against cyberattacks available to small to medium-sized businesses (“SMBs”), such as in the cannabis sector, through expert assessment of client risk and consultancy with a virtual chief information security officer (“vCISO”) who provides security oversight on a contract basis that saves the client from having to employ an in-house CISO. Such arrangements provide a more affordable cybersecurity response to SMBs that may find it desirable to avoid adding a staff position for protecting vital financial and operational information. SideChannel has extensive experience helping startups and those with industrial controls, such as cannabis companies — freeing up team members to focus on growing their operations and distribution channels (https://ibn.fm/Ww01z). SideChannel employs more than 20 C-suite-level information security officers who collectively have a combined 450 years of experience between them. The need for cybersecurity extends well beyond SMBs, of course — SideChannel’s blog reminds readers of areas in which cybersecurity intersected with large-scale real-world concerns during just the past year (https://ibn.fm/fR8At). For more information, visit the company’s website at www.SideChannel.com. NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• Methane, such as that in livestock waste, is up to 50% more potent than carbon dioxide in holding heat in the atmosphere
• EverGen is an Infrastructure platform that specializes in renewable natural gas (“RNG”) projects converting diverse types of waste into usable, green alternatives to fossil fuels
• EverGen’s RNG capacity will exceed 2 million gigajoules annually once its projects and expansions are complete in B.C., Alberta, and Ontario

We are surrounded by untapped, atmosphere-friendly energy. The sun and wind are two popular sources today, but the problem is that it isn’t always sunny or windy. For EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), the answer to decarbonizing energy lies within the endless supply of waste, such as that found on dairy farms or food waste, two large contributors to the changing climate.

EverGen is a North American leader in renewable natural gas (“RNG”). The company owns three projects in its home province of British Columbia and moved eastward in 2022, making large investments in projects in Alberta and Ontario.

RNG is manufactured through the processing of food, livestock, crops, sewage, and other types of organic waste. Run through an anaerobic digester, the output is digestate and biogas. Digestate is used for things like fertilizer, livestock bedding, and soil amendments. Biogas can be used for clean electricity or heat as is, or further processed into biomethane (another name for RNG), which is used to power vehicles or pump directly into the existing natural gas grid, where it is indistinguishable to end users as any different from conventional natural gas drilled from underground sources.

Not only is there no drilling and all the subsequent environmental impact, there is also the added perk of reducing methane emissions. Media headlines tend to treat carbon dioxide, or CO2, from cars as the only source of global warming. While a key source and present on large concentrations, CO2 is not alone. Uncaptured methane gas from cow manure is 25x-30x more potent at capturing heat in the atmosphere than CO2.

Understand that the global warming is the result of greenhouses gases trapping heat in the atmosphere rather than allowing it to radiate out into space as infrared energy, effectively putting an imaginary ceiling around the Earth to hold in extra heat. It is estimated that carbon dioxide (56.4%) and methane (16.3%) make up nearly three-quarters of all greenhouse gases, with halocarbons (11.6%), ozone (10.2%) and nitrous oxide (5.4%) comprising most of the remainder.

With auto emissions mandates sweeping the globe, countries are also turning their attention to RNG for its benefits as a green alternative to fossil fuels. The U.S. Environmental Protection Agency in December released proposed legislation under the Renewable Fuel Standard (“RFS”) program, which included highly anticipated guidance on biogas electricity and RNG. The American Biogas Council (“ABC”) applauded the proposed laws and incentives that should support additional RNG adoption, investment, and innovation.

ABC also took the opportunity to spotlight the fact that the EPA has been woefully low in its recognition of the growth rate of RNG projects’ volume, reporting 8% annually growth, rather than the 20-40% that happened. ABC believes that there is a good chance that the EPA’s forecast for 36% annual RNG volume growth during 2023-2025 is probably too conservative also.

To the north, Canada is committed to growing RNG usage. In December, the governments of Ontario and Canada agreed to invest over $11.3 million to expand CHAR Technologies’ RNG facility in Thorold, Ontario, west of Niagara Falls. The RNG and biocarbon project, currently under construction, is the only RNG facility in Canada to exclusively use woody biomass as feedstock. Phase 1 is designed to generate 20,000 gigajoules per year of RNG and 2,000 tonnes per year of biocarbon.

Through its Export Development Canada (“EDC”) export credit agency, Canada is supporting expansion of EverGen Infrastructure’s RNG projects. In August, EDC, and Scotiabank subsidiary Roynat Capital signed a term sheet providing EverGen a $31 million syndicated senior term loan, enough to fully fund the planned expansion at EverGen’s Fraser Valley Biogas (“FVB”) and Net Zero Waste Abbotsford (“NZWA”) projects.

FVB is a staple of lower BC, operating since 2011 as the original RNG project of Western Canada supplying FortisBC’s energy network. The expansion renovation is underway and expected to double the facility’s capacity to produce about 160,000 gigajoules (“GJ”) of RNG each year. Feedstock for the facility is primarily agricultural waste from local dairy farms. FortisBC wants it all, signing a new offtake agreement for up to 190,000 GJ annually.

Moving east, EverGen completed its acquisition of a 67% interest in Alberta’s Grow the Energy Circle Ltd., GrowTEC for short, which is currently in the first phase of a core RNG expansion project designed to produce ~80,000 GJ/year of RNG. Construction is nearly complete with commissioning expected any day now. The facility will then move into the second phase of the project, which is expected to produce a total of 140,000 GJ/year of RNG.

That will give EverGen 300,000 GJ of RNG annually without consideration yet for Project Radius, a 50/50 partnership between EverGen and Northeast Renewables LP. The Radius portfolio consists of three late-stage, on-farm RNG projects in southern Ontario. Collectively, the projects are expected to product approximately 1.7 million gigajoules per year of RNG from organic feedstock, cementing EverGen and Ontario as North American leaders in RNG. Construction of the three projects is slated for 2023 and 2024.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

• The California Cotton & Climate Coalition (“C4”) was created to build capacity within all stakeholders to grow, source, and develop climate-beneficial, farm-forward textiles and supply chains
• Cotton grown through C4 carries the Climate Beneficial(TM) trademark, which requires a rigorous verification process during the lifecycle of the product with an emphasis on enhancing biological life
• Coyuchi recently reported an upward trajectory of 26 percent year-over-year net sales growth and an overall revenue climb of $33.3 million – promoting investment opportunities for the public through Regulation A+

Coyuchi, the gold standard in sustainable luxury home goods, uses 100% organic cotton to manufacture all of its textiles. The company was built on four foundational pillars: protecting the planet, innovating circular design, living sustainably, and enriching the community. In line with this mission, Coyuchi has joined a coalition of companies working together to evolve California’s cotton-growing industry. The California Cotton & Climate Coalition (“C4”) aims to build capacity within all stakeholders to grow, source, and develop climate-beneficial, farm-forward textiles and supply chains. C4 includes Coyuchi, Mate, Outerknown, Reformation, Trace, Circular Systems, Imperial Yarn, Carhartt, Natural Fiber Welding, Laguna Enviro Fabrics, and opportunities for additional companies to join the coalition. These companies are a vital part of the coalition’s ecosystem, which includes farms and farmers, as well as companies purchasing cotton, the coalition team, technical service providers and scientists, and textile development partners (https://ibn.fm/heYax). Led by Fibershed, the cotton grown through the project carries the Climate Beneficial(TM) trademark. The program was designed to scale the implementation of carbon farming practices within the working landscape of California’s Central Valley, benefiting growers, rural communities, the environment, and textile brands working to enhance direct relationships with the people who grow food and fiber. Climate Beneficial(TM) requires a careful verification process, with soil and water infiltration testing, annual monitoring, and continuous trialing of growth methods, to achieve its goals. The program’s focus is to enhance the biological life within irrigated cropland soils, improve soil structure, soil-water holding capacity, natural fertility, and carbon drawdown. This will help increase resilience to drought, counter erosion, and benefit the climate. Coyuchi has seen a very positive trajectory, coming off a 26 percent year-over-year net sales growth in 2021 with an overall revenue climb of $33.3 million. The company recently opened up to outside investors through a Regulation A+ offering (manhattanstreetcapital.com/coyuch) and has exceeded the $1 million mark in funding through its campaign. Previously, Coyuchi itself attracted $20 million in private investor funding from several venture capitalists, including Saffron Hill Ventures. With a focus on stability, Coyuchi’s CEO, Eileen Mockus, believes that the company is well positioned, particularly due to the demand from millennial customers seeking sustainable product options. “We’ve been working on this for years, and we don’t see any indication that customers will be pulling back from this. It’s here to stay,” Mockus said (https://ibn.fm/mLjxx). Regarding C4, Mockus also underlined that no singular brand, farm, retailer, or researcher, has the power or influence to mobilize the change necessary to balance our climate. “Sustainability, especially in textiles where there are so many players in the supply chain, is only achievable when everyone gets a seat at the table – and that’s what makes C4 so crucial,” she added. Mockus also explained that never before have there been so many voices united toward the advancement of regeneration. “Coyuchi is proud to be a founding brand of the Coalition and hopes to influence other businesses to join us on this journey.” For more information, visit the company’s website at www.Coyuchi.com. NOTE TO INVESTORS: The latest news and updates relating to Coyuchi are available in the company’s newsroom at https://ibn.fm/COYU

• The Inflation Reduction Act provides consumers with rebates and tax credits towards energy-efficient purchases
• Homeowners will be able to claim as much as $14,000 per household, with the largest credits destined towards the purchase of heat pumps
• GeoSolar Technologies is a key supplier of heat pumps to North American households as part of its revolutionary SmartGreen(TM) Home solution
• Its renewable energy systems enable households to lower both, their carbon footprint as well as their utility bill outlay

Starting January 1st, 2023, going green could be the most cost-effective option for you. The recently passed Inflation Reduction Act provides consumers and homeowners with a host of rebates and tax credits towards energy-efficient purchases, such as appliances, electric vehicles and solar panels. In fact, homeowners could be eligible for rebates amounting to as much as $14,000 for the purchase of energy-efficient items, with the largest credits and rebates available for heat pumps, a high-efficiency system that heats and cools homes in place of conventional furnaces or air conditioners (https://ibn.fm/fRyVL).

“While the upfront cost for a heat pump may be higher, these incentives will definitely help. And over the long term, you might save money depending upon where you live and what fuel and electricity cost in your area,” said Paul Hope from Consumer Reports.

Heat pumps form an integral part of the technology offered by GeoSolar Technologies (“GST”), a Colorado-based climate technology company pioneering an approach into clean energy solutions for households. GeoSolar Technologies have sought to build upon the growing move towards renewable energy adoption thorough a multi-pronged approach which looks to electrify homes using green energy sources. From solar panels on roofs, through to geothermal heat pumps which take advantage of the warmth of the earth’s core and advanced CERV 2 air purification systems designed to manage indoor air quality in an efficient and intelligent manner, GeoSolar’s proprietary SmartGreen(TM) Home solution has been designed to dramatically increase the energy efficiency of a conventional household.

Moreover, the technology voids the need for households to depend on conventional utilities or pay utility bills. In fact, a study carried out by the company found that a traditional utility-powered home would possess a carbon footprint of upwards of 8 tons of CO2/year whilst paying annual utility bills of $2,700; in contrast, a GeoSolar-powered home would result in a negligible carbon footprint whilst disbursing less than $100 per annum in utility bills (https://ibn.fm/bCADL).

The adoption of renewable energy systems, such as household solar panel systems, has been relatively lackluster in recent years despite their longer-term economic benefits – largely due to their elevated upfront costs. A residential solar power system can cost anywhere between $3,500 to $16,000, with the wide range a factor of the system being installed as well as the type of panels being utilized (https://ibn.fm/XpZvw).

A key provision contained within the Inflation Reduction Act includes the long-term extension of the investment tax credit, a subsidy which has been instrumental in launching the US solar industry as we know it today. The bill calls for a 10-year extension of subsidies in the form of tax credits valued at 30% of the cost of the installed equipment, which will then step down to 26% in 2033 and 22% in 2034. Moreover, the tax credit also applies to residential adopters of solar technology; in effect, the 30% credit will retroactively apply to anyone who installed their system dating back to the beginning of 2022.

The act has already started to have a dramatic effect, both on solar energy installations as well as the adoption of green energy home solutions, such as the ones offered by GeoSolar Technologies. Solar accounted for 45% of all new electricity-generating capacity added to the US grid through the third quarter of 2022, more than any other electricity source (https://ibn.fm/Ojm08).

“With long-term incentives for clean energy deployment and manufacturing, the solar and storage industry is ready to create hundreds of thousands of new jobs and get to work building out the next era of American energy leadership. This is a crucial window of opportunity that we cannot miss,” stated Abigail Ross Hopper, president of the Solar Energy Industries Association (https://ibn.fm/gl0QB).

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria, a global innovator in drug delivery platforms, has developed the patented DehydraTECH(TM) platform technology, which has been shown to increase the bio-absorption of various fat-soluble active molecules and drugs
• In a recently completed study, Lexaria showed that DehydraTECH-processed CBD had exceptional safety and tolerability profile in addition to resulting in a statistically significant lowering of 24-hour ambulatory blood pressure
• The company also reported that it had demonstrated superior CBD blood absorption levels in its HYPER-H21-4 study from DehydraTECH-CBD relative to those of published comparators
• At the lowest (3.38 mg/kg) and highest (4.46 mg/kg) dose levels tested, DehydraTECH-CBD resulted in 45.8% and 133.4% higher average blood plasma levels, respectively, than the figure reported when a higher (5 mg/kg) dose level of non-Lexaria, pharmaceutical-grade CBD was administered

Global innovator Lexaria Bioscience (NASDAQ: LEXX) has developed a proprietary platform technology that is capable of delivering certain drug molecules more effectively into the human body than their generic forms. That, CEO Chris Bunka contends (https://ibn.fm/yJIUi), allows for various efficiencies and decreases in adverse side effects. Known as DehydraTECH(TM), the patented technology can be easily incorporated into the formulation and manufacturing processes of existing or new orally ingestible and topical products, according to the company, provided the products are fat soluble. So far, Lexaria has been able to process various active molecules and drugs, including antiviral drugs, nicotine, cannabidiol (“CBD”), vitamins, phosphodiesterase inhibitors, and more, using its DehydraTECH platform technology (https://ibn.fm/7pkwz). Moreover, the company has, as of December 29, 2022, received a total of 28 patents granted worldwide (https://ibn.fm/uuNFW) for several DehydraTECH-processed applications. But what is even more remarkable is the fact that Lexaria has evidenced, through multiple animal and human studies, that its DehydraTECH platform technology increases bio-absorption by up to 10x, reduces the time of onset from as much as 1-2 hours to just minutes, delivers drugs more effectively into the bloodstream, and masks unwanted tastes. And in what adds to the company’s repository of the proven benefits of DehydraTECH, the company recently completed a randomized, double-blinded, placebo-controlled cross-over study of 66 male and female volunteers, its most comprehensive hypertension study yet. Dubbed HYPER-H21-4, the study showed that DehydraTECH-processed CBD had an exceptional safety and tolerability profile. It also evidenced that the formulation resulted in a statistically significant lowering of 24-hour ambulatory blood pressure (“BP”), with the BP lowered for the entire five-week study duration. Furthermore, the BP lowered both for patients not taking any other antihypertensive drugs as well as those currently on antihypertensive medication (https://ibn.fm/Vdk4I). At the time of announcing the results from this study, the company on October 27 stated that “additional study endpoint analyses as described in the complete study protocol are still underway and any relevant material findings will be reported upon in due course….” And in a December 21 news release, Lexaria reported on one of these findings. According to this recent announcement, Lexaria reported that it had demonstrated superior CBD blood absorption levels from its patented DehydraTECH-CBD compared to those of published comparators. In their analysis, Lexaria’s researchers compared the average blood plasma levels of DehydraTECH-CBD at various dose levels (after the steady state or the amount of time needed before a consistent dose of drug achieves a stable plasma level had been reached) with that of non-Lexaria, pharmaceutical-grade CBD formulations published in two studies – a 2017 clinical trial and a 2019 study (https://ibn.fm/qZ30D). The 2017 trial evidenced an average blood plasma CBD level of 23.0 ng/ml after 22 days (the steady state) of daily dosing at a 5 mg/kg non-Lexaria CBD dose level. Lexaria’s HYPER-H21-4 study, on the other hand, showed that the DehydraTECH technology resulted in a 45.8% higher average blood plasma level (33.3 ng/mL) at DehydraTECH-CBD’s lowest dose level tested of just 3.38 mg/kg. When the dose level was increased to 4.46 mg/kg (the highest in the test), the blood plasma level was 133.4% higher than in the 2017 study at 53.7 ng/mL. On their part, the researchers in the 2017 study evaluated higher CBD dosing at a level of 10 mg/kg, showing a blood plasma level of 62.1 ng/mL. Lexaria’s HYPER-H21-4 study, however, did not see the need to administer a dose as high as 10 mg/kg, with the researchers instead extrapolating the administered dose levels linearly to 10 mg/kg. According to the resulting data trend, a 10 mg/kg dose of DehydraTECH-CBD would result in a plasma level of 149.5 ng/mL, a 141% improvement over the findings contained in the 2017 study. Using the extrapolated data trend, Lexaria also showed that at a dose level of 10 mg/kg, the absorption resulting from the administration of DehydraTECH-CBD would outperform that of the pharmaceutical-grade, synthetic CBD formulation used in the 2019 study. The non-Lexaria synthetic CBD, the 2019 study showed, reached a blood plasma level of 91 ng/mL. By comparison, Lexaria’s linear extrapolation showed that DehydraTECH-CBD absorption would outperform this figure by 64%. “DehydraTECH-CBD has repeatedly shown that it can be administered at much lower dose levels than other CBD formulations to achieve effective levels within the bloodstream, as supported by this pharmaceutical-industry peer comparison,” commented Bunka. “This is extremely important to patients hoping to achieve positive health outcomes while using lower levels of medication with no serious side effects and also important to Lexaria as we pursue FDA registration of DehydraTECH-CBD.” Lexaria hopes to file an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) this year in anticipation of possible approval to proceed with registered clinical trials evaluating the safety, tolerability, and effectiveness of DehydraTECH-CBD in treating hypertension. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Correlate, through its two subsidiaries, Correlate, and Solar Site Design, is offering a complete suite of proprietary clean energy assessment and fulfillment solutions, viewing such solutions as integral to mitigating the effects of climate change
• The WMO estimated that 2022 would likely be 1.15 degree Celsius warmer than pre-industrial times. It also projected, with a 93% probability, that one of the next five years would be warmer than 2016, which was the warmest year on record at about 1.28 degree Celsius hotter than pre-industrial times
• The spike in temperatures, according to the WMO, will be influenced mainly by countries’ suboptimal efforts to enforce effective climate change action, as has been the case over the past few years
• Correlate continues to drive forward the discussion around clean energy, while also reducing the barrier of entry, allowing real estate owners, businesses, and entire industries, to go green

Correlate Infrastructure Partners (OTCQB: CIPI) is forging a path for big and small companies to utilize energy more efficiently while lowering their overall carbon emissions. Through its two subsidiaries, Correlate and Solar Site Design, the company offers a complete suite of proprietary clean energy assessment and fulfillment solutions, stemming from the understanding that scaling distributed clean energy solutions is key to mitigating the growing effects of climate change. As a tech-enabled development, finance, and fulfillment platform for distributed solutions across North America, Correlate understands the weight of the current climate situation. The company recognizes a looming crisis that, left unattended, could result in irreversible damage to the global climate. Its push for renewable energy, as such, is defined by good intentions. Nevertheless, correlate is optimistic that as time progresses, the uptake of its distributed energy solutions will increase, thus contributing to greener buildings and an overall reduction in their carbon footprint. The World Meteorological Organization (“WMO”) estimated that 2022 was likely to be 1.15 degrees Celsius warmer than pre-industrial times. It further projected, with a 93% probability, that one of the next five years would be warmer than 2016, which was the warmest year on record at about 1.28 degree Celsius hotter than pre-industrial times. According to the WMO, this will largely be influenced by countries’ suboptimal efforts to enforce effective climate change action, which has continued to be the case over the past few years (https://ibn.fm/BaSXu). Correlate It is optimistic that their affordable energy solutions will not only initiate but also sustainably support clean energy adoption, and numbers on the ground are proof of the company’s successful approach. Correlate and Solar Site Design already have an opportunity pipeline of over $100 million in commercial projects with over $20 million in awarded backlog. In addition, the company is confident that even more companies will adopt clean energy alternatives as it progresses into the new year, ultimately presenting an even bigger opportunity for its growth. “We are excited to be at the forefront of an industry that is at an inflection point, and we are eager to begin working to change the way commercial real estate owners optimize energy assets,” noted Todd Michaels, Correlate’s CEO (https://ibn.fm/4Z0wS). If overall global temperatures are to drop, then renewable energy ought to be adopted by the masses. Correlate is encouraging this adoption and aiding companies to use energy more efficiently with fewer carbon emissions. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• International cannabis operator Flora Growth Corp. is rapidly expanding its global footprint and Colombia-based international supply chain thanks to strategic acquisitions during the past several months
• Flora’s most recent acquisition was concluded just before Christmas on finalization of an agreement with multi-national operator Franchise Global Health Inc. that strengthens Flora’s position in Europe
• Franchise Global Health (“FGH”) serves 1,200 pharmacies in Germany, which the companies regard as the doorway to the rest of Europe, and it also has a footprint in Portugal and Denmark, while Flora Growth has completed exports to Switzerland and the Czech Republic
• Flora reported a 604 percent YOY increase in revenues for the first half of the year and recently added an increase of 414 percent YOY for the Q3 period

Cannabis cultivator and global distributor Flora Growth (NASDAQ: FLGC) is entering the new year with its latest acquisition completed, opening the way for accelerated expansion into Europe’s marketplace. Franchise Global Health Inc. (TSX.V: FGH) announced Dec. 23 that it had completed arrangements for Flora Growth to acquire its issued and outstanding shares, and that the former holders of common shares of Franchise Global Health would be delisted from the TSX Venture Exchange on or about Dec. 28 as the company ends its public reporting obligations (https://ibn.fm/qYmTA). Franchise Global Health Inc. serves 1,200 pharmacies in Germany through its wholly owned subsidiaries ACA Muller and Phatebo, and the company’s acquisition by Flora Growth will provide FGH with important cannabis supply chain security, while Flora will be able to build on the new inroad to the German market and launch farther into Europe from there. “Our full focus is on Germany,” FGH CEO Clifford Starke said during an October webcast about the agreement. “Our strong position is on the distribution front. … Which, if this cannabis market is going to come to life, which we all believe so, … we’re extremely well positioned to go past Germany into the rest of Europe. It’s very important to understand that 75 to 80 percent of the sales in Europe are accounted in Germany.” Flora has already exported its first high-CBD dried cannabis flower products from Colombia to Switzerland and the Czech Republic. Subsidiary JustCBD, acquired by Flora earlier in the year, registered 79 products with the United Kingdom’s novel foods standards agency as well. Flora operates its Cosechemos cultivation, processing, extraction and isolation facility in Colombia, a country with prime growing conditions that has undergone a renaissance in cannabis cultivation during the past few years as the national government has achieved a framework for legalizing the export of select cannabis products. Flora reported a 604 percent increase YOY in its H1 revenues, and its Q3 financials showed similar momentum as revenue for the three-month period ended Sept. 30 came in at $10.8 million, an increase of 414 percent year over year accompanied by a 703 percent YOY growth in gross profit (https://ibn.fm/xdpYK). In addition to FGH’s early mover advantage in Germany, the company has a footprint in Portugal and Denmark, offering further potential for Flora’s European market ambitions (https://ibn.fm/f9F6K). For more information, visit the company’s website at www.FloraGrowth.com. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• BiondVax Pharmaceuticals was recently featured in a research report by Zacks Small-Cap Research
• The report highlighted BiondVax’s recent achievements, the most notable of which is the proof-of-concept animal trial that delivered positive results suggesting that the company’s anti-COVID-19 NanoAb candidate resulted in milder and shorter illness
• The company also received support and advice from the Paul Ehrlich Institute (“PEI”), which are viewed as key toward approval for a Phase 1/2a first-in-human clinical trial
• The report estimates that BiondVax is fully funded for the next 12 months; subsequent to the report’s publication, BiondVax raised an additional $7.3 million net in an underwritten public offering
• Accounting for a ratio change in the company’s ADS and based on a probability-adjusted discounted cash flow (“DCF”) model, Zacks valued the company at $57.00 per share

Calendar year 2022 has been eventful for BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious diseases and autoimmune diseases. Recently, the company was covered in a recent research report by Zacks Small-Cap Research (https://ibn.fm/DXlTC). The report valued the company at $57.00 per American depositary share (“ADS”) against a share price of $9.87 (as of December 8) and highlighted BiondVax’s recent key milestones, starting with highly statistically significant positive results from a preclinical in-vivo proof-of-concept study of its inhaled anti-COVID-19 nanosized antibodies (“NanoAbs”). Derived from alpacas, a species native to South America, the NanoAbs exhibit superior therapeutic potential for a wide range of diseases, according to BiondVax. Its lead NanoAb candidate, designed to treat COVID-19, has exhibited significant competitive advantages over existing oral therapies and monoclonal antibodies (“mAbs”) (https://ibn.fm/aUlNb). BiondVax intends to further develop NanoAbs as drug candidates for the potential treatment of psoriasis, psoriatic arthritis, and other autoimmune diseases. In the aforementioned study, whose initial results were announced on November 29, BiondVax found that COVID-19-infected Syrian hamsters treated with its inhaled anti-COVID-19 NanoAb candidate had an average weight loss of 3.80% compared to 12.01% for the control group of animals treated with placebo (https://ibn.fm/CKKg6). In addition to the weight, researchers also tracked eight additional parameters, including but not limited to social behaviors and heart rate, which suggested that the inhaled NanoAb therapy resulted in milder and shorter illness. BiondVax anticipates this preclinical proof-of-concept trial will continue in January 2023 and will incorporate additional arms that will test lower therapeutic doses, and a protective prophylactic dose of the inhaled NanoAb, with the resulting data guiding dose selection level for the planned first-in-human trial. The company expects to initiate this Phase 1/2a human clinical trial of the inhaled anti-COVID-19 therapy in the fourth quarter of 2023. Spurring efforts even further, BiondVax announced in the summer that it received scientific advice from the Paul Ehrlich Institute (“PEI”), a part of the German national medicines agency, that addressed preclinical, clinical, and manufacturing development plans for the COVID-19 NanoAb therapy. PEI also indicated support for a combined Phase 1/2a clinical trial among patients with confirmed COVID-19 infection (https://ibn.fm/TEQAT). PEI’s advice is generally considered a first key step towards regulatory approval by the European Medicines Agency (“EMA”), the European parallel of the US Food and Drug Administration (“FDA”). PEI’s advice, the reports notes, would help avoid the need to provide standard-of-care (“SOC”) medicines before the clinical trial participants receive the NanoAb candidate. This would allow BiondVax to assess the safety and efficacy in one small-sized trial instead of two sequential trials that would typically include a large Phase 2 study. The Zacks report also touched on BiondVax’s financial results for the third quarter ending September 30, 2022. Though the company did not report any revenues, it had approximately NIS (New Israel Shekels) 29.4 million (approximately $8.3 million at the exchange rate of 3.543 NIS/US$) in cash and cash equivalents. “With a current burn rate of approximately $1 million per month, we estimate the company has sufficient capital to fund operations for the next 12 months,” David Bautz, Ph.D., the author of the research report, writes. Subsequent to the Zacks report, BiondVax raised an additional $7.3 million net in an underwritten public offering, thereby enabling the company to not only proceed apace with the COVID-19 NanoAb development but also to pursue plans to add a number of new potential NanoAb candidates for indications such as anti-IL-17 NanoAbs for the treatment of psoriasis. Meanwhile, in November, BiondVax effected a ratio change of its ADSs from 1 ADS representing 40 ordinary shares to 1 ADS representing 400 ordinary shares, akin to a reverse stock split of 1 new ADS for every 10 old ADSs. Zacks’ valuation took this ratio change into account. Put together, these factors influenced a valuation of $57.00 per ADS, which is “based on [Zacks’] probability-adjusted DCF [discounted cash flow] model that takes into account potential revenues from the NanoAb platform.” The model is highly dependent on the clinical success of the NanoAb candidates and will be adjusted accordingly based on emerging data. For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV